GC Green Cross to Contract Manufacture 15 Million Doses of Cholera Vaccine for UbioLogics

GC Green Cross announced on the 14th that it has signed a contract for the contract manufacturing (CMO) of the oral cholera vaccine 'Ubicol' with UbioLogics at its headquarters in Yongin, Gyeonggi Province.

GC Green Cross announced on the 14th that it has signed a contract for the consignment production of cholera vaccines with UbioLogics. Huh Eun-cheol, CEO of GC Green Cross (left), and Baek Young-ok, CEO of UbioLogics, are taking a commemorative photo after signing the contract.
[Photo by GC Green Cross]

This contract follows the memorandum of understanding signed by the two companies in August. Through this contract, GC Green Cross will be responsible for the contract manufacturing of the final product process (DP) of Ubicol. The contract period is until 2026, and the scale is initially set at 15 million doses.

Ubicol is an oral cholera vaccine jointly developed by UbioLogics and the International Vaccine Institute. It currently accounts for 100% of UNICEF's cholera vaccine supply.

GC Green Cross plans to participate in UbioLogics' global public health crisis response through this contract while seeking to expand its business in the CMO field. GC Green Cross's integrated finished product facility located in Ochang, Chungbuk, is capable of producing vaccines, biosimilars, antibody drugs, and messenger RNA (mRNA) products. It is equipped with fully automated facilities including aseptic filling equipment, and its production capacity reaches 1 billion doses, the largest scale in Korea.

Baek Young-ok, CEO of UbioLogics, said, "Due to increasing cholera outbreaks caused by climate anomalies and wars around the world, vaccine supply is not meeting demand. We are glad that through this contract for the final product process contract manufacturing with GC Green Cross, we can provide additional supply to UNICEF."

Heo Eun-cheol, CEO of GC Green Cross, stated, "Based on the latest facilities and over 50 years of accumulated pharmaceutical manufacturing know-how, we already have a global-level CMO foundation. Through this partnership, we plan to participate in the global public health crisis response and also open doors to expand our CMO business."